Pharmacy benefit managers (PBMs) were originally created to lower the price of drugs but may now be causing an opposite effect, raising significant questions. Will PBMs solve pricing concerns, or are anti-PBM efforts misguided?

On 4 November at 12:00 pm EDT, Associate Director Dr. Emily Walden will speak at the American Bar Association (ABA) event, “PBMs on the Hot Seat,” where she will explore the evolution of PBMs, the FTC’s 6(b) study, and potential effects on the industry.

Dr. Walden will participate in this hour-long virtual panel with Weil, Gotshal & Manges LLP Partner Michael Moiseyev and University of Southern California-Grant Associate Professor Dr. Erin Trish.